Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Patent metadata

Field	Value
Publication number	US-9808485-B2
Application number	US-201213345036-A
Country	US
Kind code	B2
Filing date	Jan 6, 2012
Priority date	Aug 5, 1999
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.

First claim

What is claimed is:

1. A method of treatment of diabetes in a subject, comprising: administering to a subject in need of treatment for diabetes—by an effective route and in an effective amount to treat diabetes, cells that: are not embryonic stem cells, embryonic germ cells, or germ cells; can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages; express telomerase; are allogeneic or xenogeneic to the subject; do not provoke a deleterious immune response in the subject; and are effective to treat diabetes in the subject,—wherein the cells are administered adjunctively to one or more other treatments, without also administering an immunosuppressive treatment adjunctively to treatment with the cells wherein the cells have not been genetically engineered to improve their immunomodulatory properties.

2. A method according to claim 1 , wherein said cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

3. A method according to claim 1 , wherein said cells are positive for oct-3/4.

4. A method according to claim 1 , wherein said cells have undergone at least 10 to 40 cell doublings in culture prior to their administration to the subject.

5. A method according to claim 1 , wherein said cells are allogeneic to the subject.

6. A method according to claim 1 , wherein said cells are administered to the subject adjunctively to another treatment that is administered before, at the same time as, or after said cells are administered.

7. A method according to claim 1 , wherein said cells are mammalian cells.

8. A method according to claim 7 , wherein said cells are human cells.

9. A method according to claim 7 , wherein said cells are derived from cells isolated from placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, or liver tissue.

10. A method according to claim 1 , wherein the subject is a mammal.

11. A method according to claim 10 , wherein the subject is human.

12. A method according to claim 11 , wherein said cells are administered to the subject in one or more doses comprising 10 4 to 10 8 of said cells per kilogram of the subject's mass.

13. A method according to claim 1 , wherein the diabetes is Type I diabetes mellitus.

14. A method according to claim 13 , wherein said cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

15. A method according to claim 13 , wherein said cells are positive for oct-3/4.

16. A method according to claim 13 , wherein said cells have undergone at least 10 to 40 cell doublings in culture prior to their administration to the subject.

17. A method according to claim 13 , wherein said cells are allogeneic to the subject.

18. A method according to claim 13 , wherein said cells are mammalian cells.

19. A method according to claim 13 , wherein said cells are human cells.

20. A method according to claim 13 , wherein said cells are derived from cells isolated from placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, or liver tissue.

21. A method according to claim 13 , wherein the subject is a mammal.

22. A method according to claim 13 , wherein the subject is human.

23. A method according to claim 13 , wherein said cells are administered to the subject in one or more doses comprising 10 4 to 10 8 of said cells per kilogram of the subject's mass.

24. A method according to claim 13 , wherein the diabetes is Type I diabetes mellitus.

25. A method according to claim 1 , wherein the cells are derived from bone marrow.

26. A method according to claim 25 , wherein the cells are derived from human bone marrow.

27. A method according to claim 13 , wherein the cells are derived from bone marrow.

28. A method according to claim 27 , wherein the cells are derived from human bone marrow.

Assignees

• Maziarz Richard
• Kovacsovics Magdalena
• Streeter Philip
• Deans Robert
• Van'T Hof Wouter
• Athersys Inc
• Univ Oregon Health & Science

Inventors

• Maziarz Richard
• Kovacsovics Magdalena
• Streeter Philip
• Deans Robert
• Van'T Hof Wouter

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P7/06

  Antianaemics · CPC title